News/Orion Pharma’s ODM-212 Granted Orphan Designatio…
GlobeNewswire🇪🇺 EUUnresolved

Orion Pharma’s ODM-212 Granted Orphan Designation for the Treatment of Malignant Mesothelioma by the European Commission

ORION CORPORATION PRESS RELEASE 23 JUNE 2026 at 9:30 EEST Orion Pharma’s ODM-212 Granted Orphan Designation for the Treatment of Malignant Mesothelioma by the European Commission

Read full release on GlobeNewswire
Orion Pharma’s ODM-212 Granted Orphan Designation for the Treatment of Malignant Mesothelioma by the European Commission